.png)
Cell and Gene Therapy Updates
- Oncofocus Team
- Jun 20
- 2 min read
February 2nd Week, 2025
📝 BMS’ Phase 2 TRANSCEND FL trial of Breyanzi (lisocabtagene maraleucel; an autologous, anti-CD19 CAR-T) met primary endpoint of ORR and key secondary endpoint of CRR in marginal zone lymphoma (MZL) cohort. Detailed results will be presented at an upcoming conference (Ref 1, 2)
❓ What are the current benchmarks in MZL?
📝 Imugene’s Azer-cel (an allogeneic, anti-CD19 CAR-T) + low dose IL-2 elicited two additional complete responses resulting in a CRR of 57.1% (4 out of 7 evaluable patients) in the Phase 1b trial in R/R Diffuse large B-cell lymphoma (DLBCL) patients, who previously failed 4-5 lines of therapy, including autologous CAR-T (Ref 3, 4)
❓ How did the inclusion of low dose IL-2 influence the outcomes?
📝 Galapagos deprioritized GLPG5201(point-of-care manufactured, an autologous, anti-CD19 CAR-T), and expanded the development of GLPG5101 (point-of-care manufactured, an autologous, anti-CD19 CAR-T) (Ref 5)
❓ What was the rationale behind deprioritization of GLPG5201?
📝 Lion TCR’s Liocyx-M004 (an autologous, HBV targeting mRNA-encoded TCR-T) received the US FDA clearance to initiate an international multi-centre Phase 2 clinical trial for the treatment of HBV-related Hepatocellular Carcinoma (Ref 6)
❓ Are there any other mRNA-encoded cell therapies under development?
📝 Due to the strategic reasons, Otsuka holdings discontinued multiple cancer assets including OPC-415 (MMG49 CAR-T targeting activated integrin β7), which is in Phase 1/2 trial conducted solely in Japan for R/R Multiple Myeloma (Ref 7, 8)
❓ What might be the reason behind the Otsuka's decision to discontinue OPC-415?
To know answers to these questions and for additional insights, write to us at support@oncofocus.com
🌐 References:
Comentários